ArticleScientific reports2026
Validity of the 2019 European Society of Cardiology Pre-Test Probability (2019 ESC-PTP) for predicting obstructive coronary artery disease among Malaysians.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The 2019 European Society of Cardiology (ESC) guideline introduced a pre-test probability (PTP) tool to estimate the likelihood of obstructive coronary artery disease (CAD). Its performance has not been validated in the Malaysian population. This study aimed to validate this tool in this setting. A cross-sectional study was conducted from June 2023 to May 2024. PTP scores were calculated using the 2019 ESC-PTP tool and stratified as low (≤ 5%), moderate (> 5%–15%), and high (> 15%) risk. For diagnostic accuracy analysis, low scores were considered negative, while moderate-to-high scores were grouped as positive tests. Reference standards were ≥ 50% luminal stenosis on invasive coronary angiography (ICA), or a Coronary Artery Disease Reporting and Data System (CAD-RADS) 2.0 score of ≥ 3 on coronary computed tomography angiography (CCTA). Diagnostic performance was evaluated using sensitivity, specificity, positive and negative predictive values (PPV, NPV), likelihood ratios (PLR, NLR), area under the receiver operating characteristic curve (AUC), and overall diagnostic accuracy. Among 194 participants, 110 (56.7%) had obstructive CAD. The 2019 ESC-PTP tool demonstrated sensitivity of 95.5% (95% CI: 90.5–98.3) and specificity of 25.0% (95% CI: 16.6–34.9). PPV was 62.5% (95% CI: 55.0–69.6), NPV 80.8% (95% CI: 63.1–92.6), PLR 1.27 (95% CI: 1.11–1.45) and NLR 0.18 (95% CI: 0.07–0.46). The AUC was 0.794 (95% CI: 0.732–0.857) with an overall accuracy of 64.9% (95% CI: 58.2–71.7). The 2019 ESC-PTP tool demonstrates high sensitivity, making it reliable for excluding obstructive CAD in low-risk patients. Its limited specificity restricts its role in confirming disease, highlighting the need for further testing in moderate-to-high risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.